Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Amit Sanyal, MD: A Clinician’s Perspective

Dec

Today In Oncology

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Related Videos

Deborah Collyar: What's In It for Patients?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Amit Sanyal, MD: A Clinician’s Perspective

Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL

GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers

Deb Schrag Elected 2027–2028 ASCO President

NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer

Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns